Cancer Drug
Latest news and updates related to cancer drug
About Cancer Drug coverage
The Cancer Drug news hub on Global Investing News tracks 9 recent headlines that matter to investors, policy watchers, and market strategists. Use this page to monitor how Cancer Drug developments affect earnings expectations, sector rotation, supply chains, regulation, and cross-asset volatility. Stories are grouped by source type — market data, company announcements, regulatory filings, and expert analysis — so you can scan the signal quickly without wading through duplicate wire copy. When a headline links to a full article, you will find expanded context, key facts, and prediction-market angles where available. Bookmark this hub if you follow Cancer Drug across quarters; new items are added as our crawl pipeline ingests fresh sources throughout the trading day.
Explore related topics
Latest Cancer Drug headlines
Market Data
(5)Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
Top Midday Stories: Goldman Shares Fall Despite Q1 Earnings Topping Estimates; Revolution's Pancreatic Cancer Drug Met Key Study Goals
Top Midday Stories: Goldman Shares Fall Despite Q1 Earnings Topping Estimates; Revolution's Pancreatic Cancer Drug Met Key Study Goals
Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress
Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress
AstraZeneca Sees Further Growth, Lifted by Cancer Drugs
AstraZeneca Sees Further Growth, Lifted by Cancer Drugs
Other Sources
(3)Akeso Confident of Cancer Drug's FDA Approval Odds
Akeso, a Chinese biotech company, has expressed high confidence in securing U.S. Food and Drug Administration (FDA) approval for its cancer drug, potentially AK104 (a PD-1/CTLA-4 bispecific antibody), based on promising clinical trial data and ongoing discussions with regulators. This optimism suggests the company believes its drug meets the efficacy and safety standards required for market entry in the lucrative U.S. oncology market.
Jacobio Strikes New Cancer Drug Deal with AstraZeneca
Chinese biotech firm Jacobio Pharmaceuticals has entered a significant licensing agreement with pharmaceutical giant AstraZeneca. This deal involves Jacobio granting AstraZeneca exclusive global rights to develop and commercialize a novel cancer drug, a SHP2 inhibitor, which holds promise for treating various solid tumors.
One Generic Cancer Drug Costs $35. Or $134. Or $13,000
This Bloomberg article highlights the extreme and arbitrary pricing discrepancies for generic cancer drugs, revealing that the cost can vary wildly from tens to thousands of dollars for the same medication. This disparity often depends on factors like pharmacy, insurance coverage, and manufacturer, creating a significant burden and confusion for patients and healthcare systems.
Get alerts for this topic
Subscribe to receive updates about "Cancer Drug"